查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862965

体外肺模型市场：依模型类型、应用、细胞来源、技术、产品类型和最终用户划分－2025-2032年全球预测

In Vitro Lung Model Market by Model Type, Application, Cell Source, Technology, Product Type, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，体外肺模型市场规模将达到 25.0275 亿美元，复合年增长率为 17.48%。

关键市场统计数据
基准年 2024 6.8938亿美元
预计年份：2025年 8.1258亿美元
预测年份 2032 2,502,750,000 美元
复合年增长率 (%) 17.48%

科学和监管的共同推动，正将体外肺模型发展成为核心的临床前资产，从而重塑转化和商业化策略。

呼吸系统研究和临床前试验领域正经历显着的变革时期，这主要得益于科学技术的进步、监管机构对与人体相关的模型日益重视，以及减少动物试验依赖的迫切需求。体外肺模型，包括二维培养、3D类器官、晶片器官平台和精密切片组织，正与细胞来源、微加工和生物工程领域的创新相结合，为疾病建模和药物测试提供更具预测性和扩充性的替代方案。这种融合正在重塑研究人员检验作用机制、筛检候选药物和评估呼吸毒性的方式。

在慢性肺病和急性肺病领域持续存在未被满足的需求之际，製药和生物技术开发商正加速推进呼吸系统药物研发管线，而这些进展也正是在此背景下涌现。同时，监管机构和伦理监督机构对支持安全性和有效性声明的人体相关数据提出了更高的要求。这些驱动因素共同作用，正推动体外肺模型从专业的学术工具转变为转化研究策略的核心组成部分。本导言概述了技术、监管和商业性因素如何相互作用，重新定义临床前阶段可靠性和可扩充性方面的预期，为后续的深入专题分析奠定了基础。

技术整合和跨部门合作正在将客製化的体外肺部实验转变为可扩展、检验的平台，从而指导监管和商业性进程。

体外肺模型领域正从孤立的概念验证实验转型为支持药物发现、开发和监管互动决策的整合平台。微流体、支架工程和干细胞分化技术的成熟使得所建构的模型更真实地模拟肺泡和支气管的微环境、细胞异质性和动态力学作用。这使得研究人员能够以更高的生理保真度探索疾病机制，并测试从小分子药物到生物製药和细胞疗法等各种治疗方法，从而提高其临床应用价值。

随着技术进步，学术界、产业界和受託研究机构(CRO) 之间的合作正在加速模型标准化、可重复性研究以及与临床终点的交叉检验。这些合作透过建立共用通讯协定和品质标准，降低了模型应用的门槛。此外，整合高内涵成像、多体学数据和人工智慧驱动分析的数位化增强技术提高了体外实验的可解释性，并能够更详细地分析细胞反应的表型。这些变革正将体外肺模型从客製化的实验工具转变为可扩展、检验的平台，并可纳入监管策略和商业开发流程。

关税政策引起的供应链变化可能会促使筹资策略重组，并促进体外肺模型材料的本地化生产。

关税政策的变化会影响设计、製造、分销和采购体外肺模型技术和试剂的机构的营运决策。影响进口实验室设备、微流体组件和​​专用生物试剂的贸易措施可能会改变采购计画和单位经济效益，尤其对于依赖跨境供应链的研究团队和公司而言更是如此。如果关税增加关键材料的到岸成本，机构可能需要考虑短期调整措施，例如寻找替代供应商、提前采购或本地生产，以维持实验的连续性。

除了直接的成本影响外，关税驱动的供应链变化可能会加速生产和分销网络的战略本地化。企业可能会寻求加强与区域供应商的关係，或投资于国内製造能力，以减轻关税波动的影响。同时，受託研究机构和研究机构可能会扩大供应商范围，纳入受关税影响较小的市场的供应商，并优先考虑能够缓衝成本突发波动的库存管理策略。随着时间的推移，这些调整可能会影响研发中心和专业製造群的分布，进而影响区域竞争格局以及先进体外肺模型技术的获取途径。

多层细分框架揭示了模型类型、应用领域、电池来源、技术、产品类型和最终用户需求如何汇聚，从而塑造采用趋势和策略重点。

在体外肺模型领域，建立精细的市场区隔框架对于理解客户需求、技术适用性和实际效用至关重要。依模型类型划分，市场涵盖二维细胞培养、3D器官、晶片肺系统和精密切割肺切片。二维细胞培养可进一步区分细胞株和原代细胞培养，这反映了二者在通量、生理相关性和获取复杂性上的差异。三维类器官则分为肺泡类器官和支气管类器官，分别满足不同的疾病建模和药物反应分析需求。基于应用领域的细分可以明确最终用途，例如疾病建模、药物发现与开发、个人化医疗和毒性测试，并将特定的实验目标与最佳模型类别连结起来。细胞来源分析则区分了动物性细胞、细胞株和人源性细胞。人源细胞进一步细分为原代细胞和干细胞衍生细胞，这一划分对转化应用和监管合规性有显着影响。基于技术的分类重点在于微流体技术、支架培养和无支架培养。微流体系统进一步分为连续流系统和液滴系统，支架培养又分为天然支架和合成支架，无支架培养则分为生物反应器和悬滴培养。每种选择都代表着复杂性、扩充性和生理模拟性之间的权衡。产品类型着重于仪器和试剂套件/试剂，最终用户涵盖学术研究机构、受託研究机构(CRO)、製药和生物技术公司以及监管机构。将这些细分市场与客户优先事项结合，可以揭示生理保真度、通量、成本效益和监管相容性等方面的需求趋同或分歧之处，从而帮助平台提供者识别策略机会，优化其针对不同使用者群体的价值提案。

区域生态系统和政策框架导緻美洲、欧洲、中东和非洲以及亚太地区体外肺模型的应用模式存在差异。

区域趋势影响人才、资本、法规结构和製造生态系统的获取，而这些都对体外肺模型的开发和应用至关重要。美洲拥有高度集中的转化研究中心、生物技术丛集和受託研究机构（CRO），这有利于新型平台的快速部署，并促进学术研究人员和商业开发人员之间的合作。该地区的法规环境和支付方结构也推动了对与人体相关的模型的需求，这些模型可以缩短开发週期并降低后期失败的风险。

在欧洲、中东和非洲地区，严格的监管要求、伦理框架以及强大的产学合作共同促进了严谨的模型检验和统一标准的发展。公私合营以及对转化研究中心的投资支持了跨国技术扩散，而重点国家的国家战略则优先加强先进生物工程能力。在亚太地区，产能的快速扩张、大规模生产能力以及不断完善的临床研究基础设施，使该地区成为体外肺模型技术的重要生产和消费区域。政府支持的创新计画和不断壮大的生物技术人才库也在推动区域市场成长，为本地生产和大规模应用创造了有利环境。

市场领先的公司正在建立一个平台生态系统，该生态系统整合了设计模型、标准化通讯协定和数位分析，以降低采用门槛并提高转换研究的可靠性。

体外肺模型领域的竞争格局呈现出技术供应商、设备製造商、试剂开发商和服务型合约检验受託研究机构（ CRO）并存的局面。主要企业正致力于打造兼具卓越技术和生物学保真度的平台能力，许多企业也透过策略联盟寻求转化验证和市场拓展。将模组化硬体与灵活的试剂套件相结合的企业更有可能吸引更广泛的终端用户，因为它们降低了实验的技术门槛，同时支援高级应用客製化。

市场领导的一个显着趋势是寻求将模型平台与数位分析和标准化通讯协定相结合的生态系统策略。这些策略透过解决可重复性问题并简化从药物发现到临床前测试的工作流程中的数据集成，降低了准入门槛。此外，积极与监管机构和标准化联盟合作的公司可以透过塑造检验范式和明确产品申报的证据要件而获得优势。对于新参与企业而言，针对特定疾病领域或测试方案中未被满足的需求的利基能力——例如专用类器官系、专有支架化学或独特的微流体架构——通常是其差异化优势的来源。拥有技术专长和可扩展营运能力的服务供应商仍然是寻求外包复杂检测并加快结果获取速度的机构的重要合作伙伴。

应优先考虑交叉检验、模组化产品设计、策略合作、本地采购数位资料集成，以推动产品采用并降低营运风险。

产业领导者应优先考虑加快检验、扩大可及性，并使平台开发与监管和临床证据要求保持一致。首先，应投资进行交叉验证研究，将体外模型输出与特征明确的临床终点和已建立的体内基准进行比较，以增强转化相关性的论点。其次，应开发模组化产品套件，提供清晰的升级路径，将支援高通量筛检的基础配置与能够为后期研究提供更高生理复杂性的高阶模组相结合。第三，应加强与合约研究机构和学术机构的合作，建构共用的检验资料集，并扩大对最终用户的技术支援。

同时，企业应尽可能实现供应链环节本地化，以降低关税风险并缩短关键零件的前置作业时间。建立以最佳实践、数据解读和监管要求为重点的客户教育项目，将有助于降低采用门槛并增强市场信心。最后，投资于数位化分析和标准化资料格式，将使客户能够把体外实验结果与多体学和临床数据集整合，从而透过清晰的决策路径和下游商业化途径，增强模型采用的商业价值。

我们采用透明且多角度的调查方法，结合专家访谈、同侪审查证据、监管文件和情境分析，以支持我们可靠的见解和建议。

本报告整合了定性访谈、二手文献以及结构化的技术检验框架，以得出平衡且可重复的分析结果。主要资料来源包括与学术界、受託研究机构和商业领域的科学家、研发负责人和采购专业人员进行深入讨论，以了解买方需求、技术挑战和检验预期。次要资料来源包括同行评审出版物、监管指导文件、专利概况和公司披露信息，以确定技术蓝图和实用化证据。

我们的分析方法结合了技术比较评估和基于情境的供应链分析，以评估采购和政策变数（包括关税和区域製造能力）对采用趋势和策略定位的影响。我们的细分市场映射方法采用属性驱动的方法，将模型类型、应用、电池来源和技术与用户优先级和证据要求相匹配。在整个研究过程中，我们强调三角验证和透明度：所有论点均有多重资料输入支持，方法论假设均有记录，并且在证据不确定的领域中明确阐述了局限性。这种方法确保了我们的结论和建议建立在充分论证的基础上，结合了技术见解、相关人员的观点和可观察的市场行为。

要实现其转化潜力，严格的检验、支持性的生态系统和策略性的商业化对于将体外肺模型的进展转化为持续的临床和商业性价值至关重要。

体外肺模型正从研究热点转变为基础工具，对药物发现、安全性评估和转化决策有重大影响。微流体、人工支架和干细胞生物学等技术的融合，使得建构生理保真度更高的模型成为可能；同时，数据分析技术的进步也为深入解读细胞反应提供了可能。这些进展，加上不断变化的监管要求和策略性供应链重组，意味着能够将检验的体外数据整合到研发流程中的企业，将在降低临床专案风险和缩短产品上市时间方面获得竞争优势。

采用情况不会一成不变，而是会因细分市场和区域趋势的不同而有所差异。投资于检验、标准化和客户支援的公司将加快并扩大采用范围。同样重要的是，策略性地关注采购韧性和伙伴关係生态系统将有助于减轻外部衝击，并为更广泛的实施创造可扩展的路径。总之，为了将技术可能性转化为组织能力，我们强调相关人员必须将科学创新与严格的检验、周全的商业性包装以及与监管机构和标准制定机构的积极合作相结合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合机械刺激的晶片器官微流体肺模型的研究进展
  • 将个人化呼吸系统疾病模型与患者来源的肺类器官结合
  • 利用3D生物列印技术建构高保真血管化肺组织
  • 利用人工智慧驱动成像和高内涵筛检进行体外肺毒性测试
  • 开发一种能够模拟机械拉伸和气流模式的动态晶片肺系统
  • 新冠病毒研究中对包含上皮细胞、内皮细胞和免疫细胞的共培养肺模型的需求日益增长
  • 推出利用先进体外肺部暴露技术的新型气溶胶药物传递测试平台
  • 推进标准化和监管途径，以期在毒性测试中接受体外肺模型数据。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 体外肺模型市场（依模型类型划分）

  • 二维细胞培养
    • 细胞株培养
    • 原代细胞培养
  • 3D类器官
    • 肺泡类器官
    • 支气管类器官
  • 晶片肺
  • 精准切割的肺片

9. 体外肺模型市场（依应用划分）

  • 疾病模型
  • 药物发现与开发
  • 个人化医疗
  • 毒性测试

10. 体外肺模型市场（依细胞来源划分）

  • 动物源性细胞
  • 细胞株
  • 人类来源细胞
    • 原代细胞
    • 干细胞衍生细胞

11. 依技术分類的体外肺模型市场

  • 微流体技术
    • 连续流系统
    • 滴灌系统
  • 基于支架的培养
    • 天然支架
    • 合成支架
  • 无支架培养
    • 生物反应器
    • 悬垂

12. 体外肺模型市场（依产品类型划分）

  • 装置
  • 套件和试剂

13. 体外肺模型市场（依最终用户划分）

  • 学术和研究机构
  • CRO
  • 製药和生物技术公司
  • 监管机构

14. 体外肺模型市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 体外肺模型市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国体外肺部模型市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Emulate, Inc.
    • MIMETAS BV
    • CN Bio Innovations Ltd.
    • Hurel Corporation
    • TissUse GmbH
    • Epithelix Sarl
    • MatTek Life Sciences, Inc.
    • InSphero AG
    • Kirkstall Ltd
    • Stemina Biomarker Discovery, Inc.
Product Code: MRR-F6513A06BD96

The In Vitro Lung Model Market is projected to grow by USD 2,502.75 million at a CAGR of 17.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 689.38 million
Estimated Year [2025] USD 812.58 million
Forecast Year [2032] USD 2,502.75 million
CAGR (%) 17.48%

A converging scientific and regulatory momentum is elevating in vitro lung models into central preclinical assets that reshape translational and commercial strategies

The landscape of respiratory research and preclinical testing is experiencing a profound transformation driven by scientific advances, regulatory emphasis on human-relevant models, and a growing imperative to reduce reliance on animal studies. In vitro lung models-encompassing two-dimensional cultures, three-dimensional organoids, organ-on-chip platforms, and precision-cut tissue slices-are converging with innovations in cellular sourcing, microfabrication, and bioengineering to offer increasingly predictive and scalable alternatives for disease modeling and drug testing. This convergence is reshaping how researchers validate mechanisms of action, screen therapeutic candidates, and assess respiratory toxicology.

These advances come at a moment when pharmaceutical and biotechnology developers are accelerating respiratory pipelines in response to persistent unmet needs across chronic and acute pulmonary conditions. Simultaneously, regulatory agencies and ethical oversight bodies are signaling stronger expectations for human-relevant data to support safety and efficacy claims. Together, these drivers are elevating in vitro lung models from specialized academic tools to core components of translational research strategies. The introduction outlines how the interplay of technological, regulatory, and commercial forces is redefining expectations for preclinical confidence and operational scalability, and sets the stage for the deeper thematic analysis that follows.

Technological integration and cross-sector collaboration are converting bespoke in vitro lung experiments into scalable, validated platforms that inform regulatory and commercial pathways

The in vitro lung model landscape is shifting from isolated proof-of-concept experiments toward integrated platforms that can feed decision-making across discovery, development, and regulatory interaction. Technological maturation in microfluidics, scaffold engineering, and stem cell differentiation is enabling models that better recapitulate alveolar and bronchial microenvironments, cellular heterogeneity, and dynamic mechanical forces. As a result, researchers can explore disease mechanisms at greater physiological fidelity and test modalities ranging from small molecules to biologics and cell therapies with improved translational relevance.

Parallel to technological progress, partnerships between academia, industry, and contract research organizations are accelerating model standardization, reproducibility studies, and cross-validation against clinical endpoints. These collaborations are reducing barriers to adoption by establishing shared protocols and quality benchmarks. In addition, digital augmentation-integrating high-content imaging, multi-omics readouts, and AI-driven analytics-is amplifying the interpretative power of in vitro assays and enabling more granular phenotyping of cellular responses. Collectively, these shifts are transforming in vitro lung models from bespoke experimental tools into scalable, validated platforms that can be incorporated into regulatory strategies and commercial development pathways.

Tariff-driven supply chain shifts can reshape procurement strategies and incentivize regional manufacturing localization for in vitro lung model inputs

Tariff policy changes can influence the operational calculus for organizations that design, manufacture, distribute, or source in vitro lung model technologies and reagents. Trade measures that affect imported laboratory instruments, microfluidic components, or specialized biological reagents can alter procurement timelines and unit economics, particularly for research groups and companies reliant on cross-border supply chains. When tariffs increase the landed cost of critical inputs, organizations must evaluate near-term adjustments such as alternative suppliers, forward buying, or localized manufacturing to preserve experimental continuity.

Beyond direct cost impacts, tariff-induced supply chain shifts can accelerate strategic localization of production and distribution networks. Firms may seek to deepen regional supplier relationships or invest in domestic manufacturing capabilities to reduce exposure to tariff volatility. In parallel, contract research organizations and research institutions may broaden their vendor base to include suppliers from tariff-insulated markets, and prioritize inventory management strategies that buffer against abrupt cost changes. Over time, these adaptations can influence where R&D centers and specialized manufacturing clusters concentrate, shaping regional competitive dynamics and access to advanced in vitro lung model capabilities.

A layered segmentation framework reveals how model type, application, cell source, technology, product type, and end-user needs converge to shape adoption and strategic priorities

A nuanced segmentation framework is essential for understanding customer needs, technology fit, and translational utility across the in vitro lung model landscape. When considering model type, the market spans 2D cell cultures, 3D organoids, lung-on-a-chip systems, and precision-cut lung slices. Within 2D cell cultures, a further distinction exists between cell line cultures and primary cell cultures, reflecting differences in throughput, physiological relevance, and sourcing complexity. The 3D organoid category separates into alveolar organoids and bronchial organoids, each serving discrete disease modeling and drug-response interrogation needs. Application-driven distinctions clarify end use across disease modeling, drug discovery and development, personalized medicine, and toxicity testing, linking specific experimental objectives to the most appropriate model class. Cell source analysis differentiates animal-derived cells, cell lines, and human-derived cells; human-derived cells are subdivided into primary cells and stem cell-derived cells, a split with strong implications for translational relevance and regulatory acceptability. Technology-based segmentation highlights microfluidics, scaffold-based cultures, and scaffold-free cultures; microfluidic systems are further categorized into continuous flow systems and droplet-based systems, scaffold-based cultures divide into natural and synthetic scaffold approaches, and scaffold-free cultures separate into bioreactor and hanging drop modalities, each choice signaling trade-offs between complexity, scalability, and physiological mimicry. Product type focuses attention on instruments versus kits and reagents, and end users span academic and research institutes, contract research organizations, pharmaceutical and biotechnology companies, and regulatory agencies. Mapping these segments against customer priorities reveals where demand for physiological fidelity, throughput, cost-efficiency, and regulatory alignment converge or diverge, and it helps identify strategic opportunities for platform providers to tailor value propositions to distinct user cohorts.

Regional ecosystems and policy frameworks are driving differentiated adoption patterns for in vitro lung models across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence access to talent, capital, regulatory frameworks, and manufacturing ecosystems that underpin the development and deployment of in vitro lung models. In the Americas, there is a concentration of translational research centers, biotech clusters, and contract research organizations that support rapid adoption of novel platforms and facilitate partnerships between academic innovators and commercial developers. The regulatory environment and payer landscapes in this region also drive demand for human-relevant models that can accelerate development timelines and de-risk late-stage failures.

Across Europe, the Middle East & Africa, the interplay of stringent regulatory expectations, ethical frameworks, and strong academic-industrial linkages promotes rigorous model validation and harmonized standards. Investment in public-private collaborations and translational research hubs supports cross-border technology diffusion, while national strategies in key countries prioritize advanced bioengineering capabilities. In the Asia-Pacific region, rapid capacity expansion, substantial manufacturing capabilities, and a growing base of clinical research infrastructure position the area as a critical producer and consumer of in vitro lung model technologies. Local market growth is also stimulated by government-backed innovation programs and an expanding biotechnology talent pool, creating fertile conditions for both localized production and large-scale adoption.

Market leaders are building integrated platform ecosystems that combine engineered models, standardized protocols, and digital analytics to reduce adoption friction and enhance translational credibility

Competitive dynamics in the in vitro lung model domain reflect a mix of specialized technology providers, instrument manufacturers, reagent developers, and service-oriented contract research organizations. Leading companies are investing in platform capabilities that blend engineering excellence with biological fidelity, and many are pursuing strategic partnerships to expand translational validation and market reach. Firms that combine modular hardware with flexible reagent suites tend to appeal to a broader set of end users because they lower technical barriers to experimentation while enabling customization for advanced applications.

An observable trend among market leaders is the pursuit of ecosystem plays that integrate model platforms with digital analytics and standardized protocols. These strategies reduce friction for adoption by addressing reproducibility concerns and by simplifying data integration across discovery and preclinical workflows. Additionally, companies that actively engage with regulatory bodies and standard-setting consortia gain an advantage by shaping validation paradigms and clarifying evidentiary expectations for product submissions. For newer entrants, differentiation often stems from niche capabilities-such as specialized organoid lines, unique scaffold chemistries, or proprietary microfluidic architectures-that address unmet needs in specific disease areas or testing regimes. Service providers that combine technical expertise with scalable operations remain key partners for organizations seeking to outsource complex assays or to accelerate time to result.

Prioritize cross-validation, modular product design, strategic partnerships, localized sourcing, and digital data integration to accelerate adoption and mitigate operational risks

Industry leaders should prioritize actions that accelerate validation, broaden accessibility, and align platform development with regulatory and clinical evidence needs. First, invest in cross-validation studies that compare in vitro model outputs with well-characterized clinical endpoints and established in vivo benchmarks to strengthen claims of translational relevance. Second, develop modular product suites that offer clear upgrade paths: basic configurations that support high-throughput screening alongside advanced modules that deliver enhanced physiological complexity for late-stage testing. Third, expand partnerships with contract research organizations and academic centers to create shared validation datasets and to scale technical support for end users.

Concurrently, companies should localize supply chain elements where feasible to mitigate tariff risk and to shorten lead times for critical components. Building customer education programs focused on best practices, data interpretation, and regulatory expectations will reduce barriers to adoption and foster market trust. Finally, invest in digital analytics and standardized data formats that enable customers to integrate in vitro outputs with multi-omics and clinical datasets, thereby amplifying the business case for model adoption through clearer pathways to decision-making and downstream commercialization.

A transparent, triangulated methodology combining expert interviews, peer-reviewed evidence, regulatory documents, and scenario analysis to support defensible insights and recommendations

This report synthesizes qualitative interviews, secondary literature, and a structured framework of technical validation to generate a balanced and reproducible analysis. Primary inputs included in-depth discussions with scientists, R&D leaders, and procurement specialists across academic, contract research, and commercial settings to capture buyer requirements, technical pain points, and validation expectations. Secondary sources comprised peer-reviewed publications, regulatory guidance documents, patent landscapes, and company disclosures that illuminate technology roadmaps and translational evidence.

Analytical methods combined comparative technology assessment with scenario-based supply chain analysis to evaluate how procurement and policy variables, including tariffs and regional manufacturing capacity, could influence adoption and strategic positioning. Segment mapping followed an attribute-driven approach that aligns model types, applications, cell sources, and technologies with user priorities and evidence requirements. Throughout the research process, emphasis was placed on triangulation and transparency: assertions are corroborated across multiple data inputs, methodological assumptions are documented, and limitations are acknowledged where evidence remains emergent. This approach ensures that conclusions and recommendations rest on a defensible blend of technical insight, stakeholder perspectives, and observable market behaviors.

Translational promise requires rigorous validation, supportive ecosystems, and strategic commercialization to convert in vitro lung model advances into sustained clinical and commercial value

In vitro lung models are transitioning from research curiosities to foundational tools that can materially influence discovery, safety assessment, and translational decision-making. Technological convergence across microfluidics, engineered scaffolds, and stem cell biology is enabling models with greater physiological fidelity, while improvements in data analytics are unlocking richer interpretations of cellular responses. These advances, coupled with evolving regulatory expectations and strategic supply chain realignments, mean that organizations able to integrate validated in vitro data into development workflows will gain a competitive advantage in de-risking clinical programs and accelerating go-to-market timelines.

Adoption will not be uniform; instead, it will reflect the nuances captured in segmentation and regional dynamics. Companies that invest in validation, standardization, and customer support will increase the speed and breadth of uptake. Equally important, strategic attention to procurement resilience and partnership ecosystems will mitigate external shocks and create scaleable pathways for broader implementation. The conclusion underscores a pragmatic imperative: to translate technological promise into organizational capability, stakeholders must pair scientific innovation with rigorous validation, thoughtful commercial packaging, and proactive engagement with regulatory and standards-setting communities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in organ-on-chip microfluidic lung models with integrated mechanical stimulation
  • 5.2. Integration of patient-derived lung organoids for personalized respiratory disease modeling
  • 5.3. Use of 3D bioprinting techniques to create vascularized lung tissue constructs with high fidelity
  • 5.4. Application of AI-driven imaging and high-content screening in in vitro lung toxicity assays
  • 5.5. Development of dynamic lung-on-chip systems simulating mechanical stretch and airflow patterns
  • 5.6. Growing demand for co-culture lung models incorporating epithelial, endothelial, and immune cells for COVID-19 research
  • 5.7. Emerging aerosolized drug delivery testing platforms using advanced in vitro lung exposures
  • 5.8. Standardization and regulatory pathways evolving for acceptance of in vitro lung model data in toxicity testing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In Vitro Lung Model Market, by Model Type

  • 8.1. 2D Cell Cultures
    • 8.1.1. Cell Line Cultures
    • 8.1.2. Primary Cell Cultures
  • 8.2. 3D Organoids
    • 8.2.1. Alveolar Organoids
    • 8.2.2. Bronchial Organoids
  • 8.3. Lung-On-A-Chip
  • 8.4. Precision-Cut Lung Slices

9. In Vitro Lung Model Market, by Application

  • 9.1. Disease Modeling
  • 9.2. Drug Discovery & Development
  • 9.3. Personalized Medicine
  • 9.4. Toxicity Testing

10. In Vitro Lung Model Market, by Cell Source

  • 10.1. Animal-Derived Cells
  • 10.2. Cell Lines
  • 10.3. Human-Derived Cells
    • 10.3.1. Primary Cells
    • 10.3.2. Stem Cell-Derived Cells

11. In Vitro Lung Model Market, by Technology

  • 11.1. Microfluidics
    • 11.1.1. Continuous Flow Systems
    • 11.1.2. Droplet-Based Systems
  • 11.2. Scaffold-Based Cultures
    • 11.2.1. Natural Scaffolds
    • 11.2.2. Synthetic Scaffolds
  • 11.3. Scaffold-Free Cultures
    • 11.3.1. Bioreactors
    • 11.3.2. Hanging Drop

12. In Vitro Lung Model Market, by Product Type

  • 12.1. Instruments
  • 12.2. Kits & Reagents

13. In Vitro Lung Model Market, by End Users

  • 13.1. Academic & Research Institutes
  • 13.2. CROs
  • 13.3. Pharmaceutical & Biotechnology Companies
  • 13.4. Regulatory Agencies

14. In Vitro Lung Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. In Vitro Lung Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. In Vitro Lung Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Emulate, Inc.
    • 17.3.2. MIMETAS B.V.
    • 17.3.3. CN Bio Innovations Ltd.
    • 17.3.4. Hurel Corporation
    • 17.3.5. TissUse GmbH
    • 17.3.6. Epithelix Sarl
    • 17.3.7. MatTek Life Sciences, Inc.
    • 17.3.8. InSphero AG
    • 17.3.9. Kirkstall Ltd
    • 17.3.10. Stemina Biomarker Discovery, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IN VITRO LUNG MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IN VITRO LUNG MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IN VITRO LUNG MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINE CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELL CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ALVEOLAR ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BRONCHIAL ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY LUNG-ON-A-CHIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRECISION-CUT LUNG SLICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ANIMAL-DERIVED CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY STEM CELL-DERIVED CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CONTINUOUS FLOW SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY DROPLET-BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY NATURAL SCAFFOLDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SYNTHETIC SCAFFOLDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY HANGING DROP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGULATORY AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IN VITRO LUNG MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY MICROFLUIDICS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-BASED CULTURES, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY SCAFFOLD-FREE CULTURES, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA IN VITRO LUNG MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 2D CELL CULTURES, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY 3D ORGANOIDS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA IN VITRO LUNG MODEL MARKET SIZE, BY HUMAN-DERIVED CELLS, 2